The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine has released its financial results for the second quarter of 2026, alongside a series of business updates.
The company outlined its progress across therapeutic areas, including initiatives in cardiovascular disease and in vivo technologies. Further details from the press release highlight strategic developments as Editas Medicine continues to advance its clinical pipeline and operational objectives.
View post on X Loading...